CJ, Shandong Luoxin Pharmaceutical Group deal

CJ Group’s CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ will receive an upfront payment and is eligible for clinical, regulatory and performance-based milestones plus double-digit royalties. Shandong will submit a clinical trial application in 1H16. ...